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ABSTRACT 
 
Background: Extended Spectrum Beta Lactamase (ESBL) producing bacterial strains are the 
major causes of nosocomial and community-acquired infections worldwide. The aim of the study 
was to evaluate the effectiveness of Brilliance ESBL Agar (BEA) (a chromogenic culture medium) 
for the detection of ESBL in comparison with Double Disc Synergy Test (DDST) and confirm 
results from both methods by Single-plex Polymerase Chain Reaction (PCR) as gold standard.  
Materials and Methods: A total of 75 clinical isolates of Escherichia coli were screened for ESBL 
production using BEA & DDST from various clinical specimens. The antibiotic susceptibility testing 
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was done by the Kirby-Bauer disc diffusion method using Cefotaxime (30 µg) and Ceftazidime        
(30 µg) discs on Mueller Hinton agar. ESBL producing strains were detected phenotypically by 
DDST and BEA at 24 h and 48 h, respectively. Isolates screened by both methods were confirmed 
using PCR for the detection of blaSHV, blaTEM, blaCTX-M genes.  
Results: The prevalence of ESBL was 61%. The sensitivity and specificity of DDST at 24 h and 
48hours incubation time was 91.3% and 89.5%, respectively. BEA showed an increase in 
sensitivity and specificity at 48 h with 97.8% and 98.0%, respectively. All ESBL producing strains 
detected by phenotypic tests were also found harboring ESBL genes (blaSHV, blaTEM, blaCTX-M) by 
PCR. 
Conclusion: The use of BEA in the screening of ESBL production was found to give much better 
results than DDST and can be used where PCR cannot be performed. 
 
 
Keywords: Brilliance ESBL agar; double disc synergy test; extended spectrum beta lactamase genes; 
antibiotic resistance. 
 
1. INTRODUCTION 
 
The irrational and inappropriate use of beta 
lactam antimicrobial drugs has led to the advent 
of resistant strains worldwide. Beta lactam 
resistance is mainly attributed to acquiring beta-
lactamase genes localized on mobile circular 
genetic elements such as plasmids or 
transposons. Most beta-lactamases discovered 
in Escherichia coli fit into ambler class A and can 
be further grouped into narrow-spectrum beta-
lactamases (e.g., TEM-1, TEM-2, and SHV-1) 
and extended-spectrum beta-lactamases 
(ESBLs) (e.g., TEM-3, SHV-5, and CTX-M) [1]. 
ESBL impart resistance to extended-spectrum 
cephalosporin, generally used to treat infections 
brought about by Gram negative bacteria. 
 
The phenotypic confirmatory tests rarely identify 
all ESBLs. Some organisms harboring ESBLs 
might possess other Beta Lactamases that can 
mask ESBL production in the phenotypic test 
thus resulting in a false negative result. 
 
One of the most common phenotypic 
confirmatory tests used for ESBL detection is 
Double Disc Synergy Test (DDST). In this test, 
third generation Cephalosporin and 
Clavulanated-Amoxicillin disc are kept 30 mm 
apart center to center, or 20 mm for increased 
sensitivity, on inoculated Mueller-Hinton agar 
(MHA) [2]. A clear extension of the edge of the 
inhibition zone of cephalosporin towards 
Clavulanated-Amoxicillin disc is interpreted as 
positive for ESBL production. Here, Cefotaxime 
and Ceftazidime which are good substrate for 
CTX-M, TEM and SHV respectively are 
employed. Cephalosporin/clavulanate synergy is 
observed in Cephalosporin-resistant isolates [3]. 
Evaluations of the double disc synergy test 
revealed sensitivities of method ranging from 
79% to 97% and specificities range from 94% to 
100% [4-8]. Sensitivity maybe reduced when 
ESBL activity is very low, leading to wide zones 
of inhibition around the Cephalosporin and 
Aztreonam discs, especially for Proteus mirabilis 
[9]. Distance between discs affects the outcome 
of the result. In isolates which are suspicious for 
harboring ESBLs are best tested using a closer 
distance (15- 20 mm) [5-7]. 
 
Chromogenic Culture media are the next 
generation of media which are truly rapid culture-
based methods used for detection of ESBL as 
well as organism identification [10]. Here, there is 
an incorporation of chromogenic enzyme 
substrate as a detection system. Chromogenic 
substrates consist of chromophor linked to an 
enzyme-recognizing part such as carbohydrate, 
amino acids or phosphate. Specific enzymes 
produced by the target micro-organism will 
cleave to the chromogenic substrate liberating 
the chromophor which highlight the micro 
organism by coloration of the grown colony. 
However, recognition and handling of colored 
colonies is an advantage in Clinical Microbiology. 
Furthermore, the recent inclusion of 
discriminatory antibiotics into chromogenic media 
has been a revolution for the explicit detection of 
ESBL from clinical specimens [10]. Currently, 
Brilliance ESBL Agar is one of the existing 
mercantile chromogenic media for detection of 
ESBL-producers. Brilliance ESBL Agar is a ready 
to use media. Its formulation contains 
Cefpodoxime (a third generation Cephalosporin). 
This is a widely recognized marker of ESBL 
resistance, in combination with additional 
antibacterial agents, to inhibit most non-ESBL 
producing organisms, yeast and gram positive 
organisms. Cefpodoxime is a widely recognized, 
reliable and selective marker for all forms           
of ESBL which can be used as a single  
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substrate [10]. This is in disparity to Ceftazidime 
which is combined with Cefotaxime to reliably 
detect ESBL in DDST. Differentiation of the most 
ubiquitous ESBL producing organisms is 
achieved through the inclusion of two 
chromogens- 5-Bromo-3-Indoxyl and N-
methylindoxyl. On Brilliance ESBL Agar, E. coli 
expressing β-galactosidase and β-glucuronidase 
appear as blue colonies (pink if β-galactosidase 
is negative). The KESC group appears as green 
colonies due to β-galactosidase and β- 
glucosidase expression respectively [10]. Few 
Studies have been done on Brilliance ESBL 
Agar. But no such research is undertaken and 
published till date where a comparative 
evaluation of diagnostic performance of Brilliance 
ESBL agar with DDST (most common 
phenotypic test for ESBL) is done. 
 
The presence of an ESBL –producing organism 
in clinical infection can result in treatment failure. 
ESBLs can be difficult to detect because they 
have different levels of activity against various 
cephalosporins. Reducing the spread of plasmid-
mediated resistance such as ESBL in hospitals 
requires its proper identification in order to 
control the spread. This study aimed to evaluate 
Brilliance ESBL Agar in the detection of ESBL 
with comparison to Double Disc synergy Test. 
 
2. MATERIALS AND METHODS 
 
Seventy five (75) pure cultures of Escherichia 
coli from a number of clinical specimens – Urine 
(37), Wound Swab (11), Vaginal Swab (18), and 
Sputum (9) were made in suspension equivalent 
in turbidity to 0.5 McFarland solutions. Antibiotic 
susceptibility testing as well as ESBL detection 
was done using the preparation. 
 
2.1 Study Area 
 
This was a hospital-based study conducted at 
Nnamdi Azikiwe University Teaching Hospital, a 
tertiary health care facility in Nnewi, South 
Eastern, Nigeria, over a 3-month period.  
 
2.2 Antibiotic Susceptibility Testing 
 
Isolates prepared in suspension equivalent to 0.5 
McFarland standards were used for antibiotic 
susceptibility testing with Ceftazidime (30 ug) 
and Cefotaxime (30 ug) (Oxoid, United 
Kingdom). The test was conducted in 
accordance with Kirby-Bauer Disc Diffusion 
Method. Zones of Inhibition were interpreted as 
concurring to Clinical Laboratory Standard 
Institute (CLSI) [11]. Controls were utilized as 
endorsed by CLSI.  
2.3 Detection of Extended- Spectrum 
Beta-lactamase 
 
Isolates which had diameter of zone of inhibition 
of ≤17 mm with Ceftazidime and ≤ 22 mm with 
Cefotaxime were suspicious for producing ESBL 
and thus subjected to screening. 
 
2.3.1 Double disc synergy test (DDST) 
 
Extended-Spectrum Beta-lactamase (ESBL) was 
detected by the Double Disc Synergy Test 
(DDST) [2,12]. The prepared suspension of the 
isolates to turbidity equivalent to 0.5 McFarland 
standards was inoculated on Mueller-Hinton agar 
plate. Clavulanated-Amoxicillin (30 µg) disc was 
placed at the center of the Mueller-Hinton agar 
plate. Ceftazidime (30 µg) and Cefotaxime          
(30 µg) discs were placed 15 mm out from the 
edge of Clavulanated-Amoxicillin disc. Incubation 
of inoculated plates at 37°C aerobically for 24h 
and 48 h was done. Observation of 
Cephalosporin/ clavulanate synergy was 
interpreted as positive for ESBL production 
[13,14]. Controls were used as recommended by 
CLSI [11].  
 
2.3.2 Brilliance ESBL agar 
 
The presence of Extended-Spectrum Beta-
lactamase (ESBL) was also detected by 
Brilliance ESBL Chromogenic Culture Medium 
(Oxoid, UK). A prepared suspension of the test 
organism to turbidity equivalent to 0.5 McFarland 
standards was inoculated on Brilliance ESBL 
Chromogenic Culture agar plate. Inoculated 
plates were incubated at 37°C aerobically for 24 
hours and 48 hours; change in color of colonies 
was observed and interpreted as per Oxoid, UK 
guidelines. E. coli ATCC 25922 and Klebsiella 
pneumoniae ATCC 700603 were used as 
negative and positive controls. 
 
2.4 Molecular Detection of 
Blashv, Blatem, Blactx-M Genes Using 
Singlex Polymerase Chain Reaction 
(PCR) 
 
Plasmid DNA was extracted according to the 
published method of Johnson and Woodford [15]. 
PCR experiment was carried out in 25 μl solution 
consisting of 0.8 mM MgCl2, 0.5U of Taq 
polymerase, 200 µM dNTPs, 1 μl template            
DNA and 1 μl of each oligonucleotide                     
primer using a master cycler (Eppendorf, 
Germany). The primers used were: SHV-              
F-51-AGGATTGACTGCCTTTTTG-31, SHV-R-51-
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ATTTGCTGATTTCGCTCG-3
1
 [16]; TEM-F-5
1
-
TTGGGTGCACGAGTGGGTTA-31, TEM-R-51-
TAATTGTTGCCGGGAAGCTA-3
1
 [17]; CTX-M-
F-5
1
-ACCGCCGATAATTCGCAGAT-3
1
, CTX-M-
R-51-GATATCGTTGGTGGTGCCATAA-31 [18]. 
Initial denaturation at 95°C for 4 minutes followed 
by 35 cycles of denaturation at 95°C for 1 
minute, annealing for 1 minute and at 48°C 
for  blaTEM and 60°C for blaSHV and blaCTX-M , 
primer extension at 72°C for 1 minute. The final 
extension step was extended to 5 minutes at 
72°C for all genes. The amplified genes were 
separated by gel electrophoresis, in 1% (W/V) 
agarose gel submerged in TBE 0.5X 
(Tris/borate/EDTA) buffer. DNA bands were 
visualized under UV illumination after being 
stained with ethidium bromide (Merck, Germany) 
and then photographed.  Klebsiella pneumoniae 
ATCC 700603 containing blaSHV, blaCTX-M and 
blaTEM genes was used as positive control while, 
Escherichia coli ATCC 25922 not containing the 
blaSHV, blaCTX-M and blaTEM genes was used as 
negative control. 
 
2.5 Statistical Analysis 
 
Non - Parametric method (Chi-square) was used 
to determine if a significant difference existed 
between results from various procedures. Where 
a significant difference exists, it was interpreted 
as P ˂ 0.05. Sensitivity and specificity was 
calculated using the conventional formulas:  
 
Sensitivity = (TP/TP + FN) × 100; Specificity 
= (TN/TN + FP) × 100. 
 
3. RESULTS AND DISCUSSION 
 
The study was done to evaluate the performance 
of Double Disc Synergy Test (DDST) and 
Brilliance ESBL Agar (BEA) in screening for 
ESBL among Escherichia coli from a collection of 
clinical specimens which includes: Urine,  
Vaginal Swab, Wound Swab and Sputum. 
Among the clinical specimens, variation in 
number of ESBL-producing E. coli isolates was 
observed between BEA and DDST (Table 1). 
The prevalence of ESBL in this research was 
61%. 
 
With the two third generations Cephalosporin 
utilized for susceptibility testing, Cefotaxime 
exhibited a better specificity and sensitivity than 
Ceftazidime. Results from the susceptibility 
analysis showed that Cefotaxime revealed 38                 
E. coli isolates while, Ceftazidime revealed 37          
E. coli isolates as likely ESBL producers. 
 
Using the DDST and BEA for ESBL screening; 
ESBL-producing isolates emerged at 24 h and 
48h incubation periods (Figs. 1, 2, 3, 4). The 
sensitivity and specificity of DDST at 24 h 
incubation time was 91.3% and 89.5% 
respectively which was the same at 48h 
incubation time. The sensitivity and specificity of 
Brilliance ESBL agar was 87.0% and 89.5%, 
respectively at 24 h with 97.8% and 98.0%, 
respectively at 48 h. Thus, an increase in 
sensitivity and specificity was observed using 
Brilliance ESBL agar (Table 2).  
 
 
 
 
Fig. 1. Culture plate of clinical isolate of Escherichia coli from urine showing a clear extension 
of the edge of the inhibition zone of cephalosporin using Co-amoxiclav disc on Mueller-Hinton 
agar was interpreted as positive for ESBL production 
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Fig. 2. Culture plate of clinical isolate of Escherichia coli from high vaginal swab (HVS) 
showing a clear extension of the edge of the inhibition zone of cephalosporin using Co-
amoxiclav Disc on Mueller-Hinton agar was interpreted as positive for ESBL production 
 
 
 
Fig. 3. Culture plate of clinical isolate of Escherichia coli from urine showing distinctive blue 
colony colouration on Brilliance ESBL agar was interpreted as positive for ESBL production 
 
Following confirmation of the screening results, 
Single-plex Polymerase Chain Reaction (PCR) 
Amplification of blaCTX-M, blaTEM blaSHV genes 
(Figs. 5, 6, 7) revealed a prevalence of 17%, 
39%, and 43% respectively across the various 
clinical specimens (Table 3).  
The resistance pattern of Escherichia coli was 
observed among Cefotaxime and Ceftazidime. It 
gave an indication for ESBL production among 
the isolates. Using the CLSI 2011 breakpoint, it 
was observed in the study that 38 E. coli isolates 
were resistant to Cefotaxime while 37 E. coli 
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isolates were resistant to Ceftazidime. Studies on 
ESBL using CLSI guidelines by Ho et al. [14] 
reported sensitivity of 57.79% for Ceftazidime 
using Kirby Beaur disc diffusion method. This 
study’s result does not correlate with Ho et al. 
[14] result as 87.0% sensitivity was observed in 
Ceftazidime. 
 
Following the outcome of the antibiotic 
susceptibility result, the E. coli isolates were 
subjected to ESBL screening using Double Disc 
Synergy Test (DDST) and Brilliance ESBL Agar. 
DDST is described as a reliable technique for 
ESBL detection [12]. The sensitivity of DDST 
from diverse studies ranges from 79% to 96%. 
The variation in sensitivity results attributes to it 
being an unstandardized method [19]. DDST is a 
less technically simple procedure with subjective 
interpretation of result [20]. 
 
The distance between antibiotic discs affects the 
sensitivity of DDST. Studies by Ho et al. [14] 
revealed the sensitivity of DDST to be 83.8% at a 
single interdisc width of 30mm. Their study also 
showed an increase in sensitivity to 97.9% by 
decrease in the interdisc width to 20 mm. In this 
study, sensitivity and specificity of DDST was 
91.3% and 89.5% respectively at 24 h which was 
the same at 48h at a single interdisc width of 
15mm. There was no significant difference (P ˃ 
0.05) among ESBL-producing isolates that 
emerged between the two incubation periods 
using DDST. The sensitivity of DDST in this 
study partially justifies studies by Vercauteren       
et al. [8] whose study showed DDST having 
sensitivity of 96.9%. Also, Ravi et al. [20] whose 
study had 94.89% sensitivity and 75.91% 
specificity for DDST. 
 
Studies have demonstrated that Brilliance ESBL 
Agar gives an advantage of easier detection of 
ESBL-producing E. coli as well as other 
members of the Enterobacteriaceae family due to 
its chromogenic properties. Results are easier to 
interpret as it employs colony coloration 
technique. E. coli is presently the most 
predominant ESBL-producing organism in 
several countries [21-23] thus; this study is of 
great clinical significance. 
 
In this study was observed that Brilliance ESBL 
agar had 98.0% specificity at 48 h which is 
significantly higher than that of DDST with 
specificity of 89.5% at 48 h. The specificity of 
Brilliance ESBL Agar in this study was higher 
than studies by Huang et al. [24] and Brown et al. 
[25] whose studies revealed a specificity of 
95.7% and 93.0% respectively. The sensitivity of 
Brilliance ESBL agar at 24 h incubation time was 
89.5% against 91.3% for DDST. The sensitivity 
of Brilliance ESBL agar at 24 h incubation time in 
this study does not correlate with Kjersti et al. 
[26] in Norway which reported 93%.  Grohs et al. 
[27] from France reported 98.6% sensitivity and 
57.9% specificity for Brilliance ESBL after 24 h 
incubation time. The sensitivity of Brilliance 
ESBL agar was higher than that observed in this 
study but vice versa. Our study showed 
increased sensitivity (97.8%) at 48 h on Brilliance 
ESBL agar, this correlates with Biane et al. [28] 
study in Cambridge shire. Biane et al. [28] 
reported an increase in sensitivity of Brilliance 
ESBL agar from 59% to 68% after 48 h 
incubation time. Consequently, there was a 
significant difference (P ˂ 0.05) among ESBL-
producing isolates that emerged between the two 
incubation periods using Brilliance ESBL agar. 
Fifty E. coli isolates which appeared negative by 
showing no colony coloration (blue colored 
colonies) at 24 h incubation time turned positive 
(blue colored) at 48 h. In addition, 20 E. coli 
isolates emerged as false positive with DDST 
showing Cephalosporin/clavulanate synergy but, 
negative with Brilliance ESBL agar. These 
isolates showed high susceptibility to Cefotaxime 
and Ceftazidime with diameter of zone of 
inhibition of ≥ 30 mm and ≥21 mm respectively. 
This justifies the accuracy of Brilliance ESBL 
agar over DDST. The sensitivity of Brilliance 
ESBL agar at 24 h in this study does not 
correlate with studies done by Gazin et al. [10] 
whose study reported 94.9% sensitivity at 24 h. 
In our study, extended incubation (48 h 
incubation) increased the recovery of ESBL 
producers without the growth of mixed                        
flora unlike reports from previous studies   
[29,30].  
 
The inclusion of Cefpodoxime in Brilliance ESBL 
agar rather than Cefotaxime and Ceftazidime (as 
in DDST) could attribute for its higher sensitivity 
over DDST. Thus, performance of Brilliance 
ESBL agar in this study justifies claims that 
Cefpodoxime is the best substrate for screening 
all ESBL types in clinical specimens [31]. 
Furthermore, CTX-M ESBL types which do not 
confer resistance to Ceftazidime have shown a 
high prevalence among clinical isolates. 
Consequently, Ceftazidime proves to be an 
unsuitable substrate alone for ESBL screening 
[31]. 
 
At the molecular level, the prevalence of blaSHV, 
blaTEM, blaCTX-M genes was 17%, 39%, 43%, 
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respectively. CTX-M genes (20 isolates) were the 
most predominant genes with SHV genes (8 
isolates) as the least predominant ESBL gene. In 
the study, blaSHV, blaTEM, blaCTX-M genes alone 
were detected. Two or more genes were not 
detected in a clinical isolate. ESBL-producing       
E. coli harboring blaCTX-M genes were observed to 
show resistance to Cefotaxime. Cefotaxime is a 
better marker for ESBL organisms harboring 
blaCTX-M genes rather than Ceftazidime [32]. The 
sensitivity and specificity of the PCR method was 
96% and 100%, respectively. 
 
 
 
Fig. 4. Culture plate of clinical isolate of Escherichia coli from High Vaginal Swab (HVS) 
showing distinctive blue colony colouration on Brilliance ESBL Chromogenic Culture Medium 
was interpreted as positive for ESBL production 
 
Table 1. Distribution of ESBL-producing Escherichia coli among clinical specimens using 
Double Disk Synergy Test (DDST) and Brilliance ESBL Agar (BEA) 
 
Clinical specimens            No. of E. coli isolates               No. of ESBL-producing isolates 
DDST BEA 
Urine 37 23 24 
Vaginal Swab                              18 9 11 
Wound Swab                               11 4 4 
Sputum 9 4 6 
Total 75 40 45 
Key: No. – Number 
 
Table 2. Distribution of ESBL-producing Escherichia coli among clinical specimens using 
Brillance ESBL chromogenic culture medium 
 
Screening method No. of ESBL 
isolates at 
24 h (48 h) 
Sensitivity 
(%) at 24 h 
Sensitivity 
(%) at 48 h 
Specificity 
(%) at 24 h 
Specificity 
(%) at 48 h 
DDST 42(42) 91.3 91.3 89.5 89.5 
BEA 40(45) 87.0 97.8 89.5 98.0 
PCR 46 nil 95.0 nil 100.0 
Key: No. – Number, % - Percentage 
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Fig. 5. Electrophoresis of PCR products for specifying CTX-M broad spectrum β-lactamases 
genes. No.1: DNA Marker (100 bp), No 2: positive control for blaCTX-M, No. 3: negative control 
No. 4, 5, 6, 7 isolates with CTX-M (550 bp) gene 
 
 
 
Fig. 6. Electrophoresis of PCR products for specifying TEM broad spectrum β-lactamases 
genes. No.1: DNA Marker (100 bp), No 2: positive control for blaTEM, No. 3: negative control,  
No. 4,5,6,7 isolates with TEM (800 bp) gene 
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Table 3. Distribution of ESBL genes among clinical specimens 
 
Clinical specimen No. of E. coli 
isolates 
No. of ESBL 
isolates 
No. of ESBL genes 
blaSHV  blaTEM blaCTX-M 
Urine 37 25 4 9 11 
Vaginal Swab                       18 11 2 4 5 
Wound Swab                        11 4 1 2 2 
Sputum 9 6 1 3 2 
Total   75 46 8 18 20 
Key: No. – Number 
 
 
 
Fig. 7. Electrophoresis of PCR products 
showing SHV broad spectrum β-lactamases 
genes. No.1: DNA Marker (100bp), No 2: 
positive control for blaSHV, No. 3: negative 
control, No. 4, 6,9,10 isolates with SHV 
(200bp) gene, No.5, 7, 8. Isolates negative for  
SHV beta-lactamase gene 
 
4. CONCLUSION 
 
ESBL continues to pose a serious public health 
threat as it receives attention from clinical 
microbiologists, policy makers as well as the 
general public. Detection methods for ESBL from 
clinical specimens should have high specificity 
and sensitivity as well as short timing in result 
reporting. Results from our study have revealed 
that Brilliance ESBL agar had a high specificity 
and sensitivity making it reliable for ESBL 
detection among ESBL-producing E. coli. This 
medium which is a ready-to-use medium allows 
easy differentiation of different bacteria based on 
colony coloration. Thus, allowing swift 
implementation of control measures by infection 
control team. Presently, routine screening for 
ESBL-producing bacteria using chromogenic 
culture medium is yet to be adopted in Clinical 
Microbiology Laboratories in Nigeria and other 
parts of the world. Although, the media is 
expensive compared to other microbiological 
media, it significantly reduce the need for 
confirmatory test like DDST or molecular test like 
PCR which is time consuming requiring 
specialized equipment and expertise. 
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